These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22357638)

  • 1. Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
    Newman MJ; Jones LT; Kraft JM; Lee AR; Lech GM; Farrell NM; Phantumvanit V; Edwards RA
    J Oncol Pharm Pract; 2012 Dec; 18(4):394-401. PubMed ID: 22357638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
    Lux MP; Hartmann M; Jackisch C; Raab G; Schneeweiss A; Possinger K; Oyee J; Harbeck N
    Breast Cancer Res Treat; 2009 Sep; 117(2):305-17. PubMed ID: 19130218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
    Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
    Cope S; Ouwens MJ; Jansen JP; Schmid P
    Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant in postmenopausal women with advanced breast cancer.
    Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    Howell A
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
    Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
    Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
    Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P
    Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K; Burum A; Jeong E; Zhong L
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
    [No Abstract]   [Full Text] [Related]  

  • 14. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
    Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
    J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
    Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
    Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A good drug made better: the fulvestrant dose-response story.
    Robertson JF; Lindemann J; Garnett S; Anderson E; Nicholson RI; Kuter I; Gee JM
    Clin Breast Cancer; 2014 Dec; 14(6):381-9. PubMed ID: 25457991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
    Ding H; Fang L; Xin W; Tong Y; Zhou Q; Huang P
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28675545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.